| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
We aimed to identify molecules and pathways involved in activated CD14+ monocyte/macrophage-lineage cells in patients with rapidly progressive interstitial lung disease associated (RP-ILD) with myositis by using an integrated miRNA-mRNA association analysis and identified molecules related to disease pathways and regulator effect network by Ingenuity Pathway Analysis (IPA) system. Twenty-six significant matched pairs of differentially down-regulated miRNA and up-regulated mRNA were by IPA. We identified 6 relevant genes associated with disease pathways. In the regulator effect network analysis by IPA, 5 predicted upstream regulators were clarified. Disease X was identified as the predicted downstream effect involved with those 6 relevant genes. In conclusion, disease X-associated pathways in monocyte/macrophage-lineage cells is involved in the pathophysiology of RP-ILD.
|
